Transcytosis vehicles and enchancers for drug delivery
US6204054A · kind A · utility
18Cited by
1References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 25, 1998 |
| Grant date | Mar 20, 2001 |
| Priority date | — |
| Expiry date | Jun 25, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Transcytosis of a physiologically-active agent that exerts its action following passage across endothelia, epithelia or mesothelia containing the GP60 receptor is enhanced by formulation with or conjugation to a transcytosis enhancer or vehicle selected from albumin and fragments thereof, anti-GP60 antibody and fragments thereof, GP60 peptide fragments, and PDI (protein disulphide isomerase) and fragments thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.